Microtech's Groundbreaking Atrial Microsensor Implantation Study Begins in the U.S.

In a significant step forward for cardiac care, Microtech, a wholly-owned subsidiary of Medinol, has announced the first-ever implantations of its innovative atrial-pressure microsensor in the United States. These groundbreaking procedures took place at New York-Presbyterian/Columbia University, where Dr. Koji Takeda, the Director of Adult Heart Transplant Surgery, successfully implanted two of these microsensors on May 16, 2025.

Innovative Technology Behind the Microsensor

The atrial microsensor developed by Microtech represents a new generation of medical devices, characterized by its remarkably small size and completely passive design—meaning it lacks any electronics or antennas. Instead, it uses ultrasound technology to receive and transmit signals. This unique configuration allows the microsensor to function both as an independent device and in conjunction with existing implants, effectively turning them into comprehensive therapeutic and diagnostic systems. Such integrated solutions can gather crucial data, enhancing patient monitoring and treatment.

In this initial round, the two microsensors were implanted in patients who had already received Left Ventricular Assist Devices (LVADs) at the same medical facility. These procedures follow a prior successful implantation of five microsensors in Israel under comparable conditions.

Dr. Takeda remarked on the ease of the implantation, stating that it took about five minutes and required only a minor adjustment to the existing LVAD procedure. This efficiency can help streamline surgical protocols in cardiac care.

Impact on Patient Monitoring

Dr. Nir Uriel, head of the Advanced Heart Failure and Heart Transplantation department at NewYork-Presbyterian, and the principal investigator for the Microtech FIH study, emphasized the impact of continuous, non-invasive heart pressure monitoring. "This capability dramatically enhances our ability to tailor patient care. It allows us to shift from symptom-based treatment to parameter-based management," Dr. Uriel explained. He expressed enthusiasm about the study's outcomes so far: "We've managed to measure this pressure accurately and repeatedly across all patients involved in the study."

In total, the Microtech FIH study in Israel aims to involve about 15 patients. CEO Dr. Yoram Richter of Medinol shared excitement about the progress seen thus far. He stated, "We are thrilled with the performance of the sensors and hope that these trends will continue, demonstrating the feasibility and accuracy of this innovative system. We are also working towards integrating these microsensors with existing medical devices, fulfilling the true promise of this technology."

Future of Diagnostic and Therapeutic Innovations

Medinol is committed to revolutionizing the paradigms of disease diagnosis and treatment. With cutting-edge technologies designed for use in various areas of the body, the company's focus is on minimizing complications in structural heart procedures and providing real-time insights into physiological parameters through implantable sensors. The vision is to challenge existing medical practices and look toward the future, expanding the reach of healthcare providers.

In collaborating with healthcare professionals and industry partners, Medinol is paving the way for the next generation of medical devices. With knowledge at their fingertips, these innovations are not just on the horizon; they are being realized today.

For additional information on Microtech and its initiatives, visit Medinol's official website or reach out to Jeff Roach, the Chief Commercial Officer, at [email protected]